<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298336</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCN10-DR-ANDREJAK-MELLE</org_study_id>
    <nct_id>NCT01298336</nct_id>
  </id_info>
  <brief_title>Treatment of Mycobacterium Xenopi Pulmonary Infection</brief_title>
  <acronym>CAMOMY</acronym>
  <official_title>Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the 6-months sputum conversion rate with a
      clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary
      infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, Mycobacterium xenopi is the second non-tuberculous mycobacteria responsible of
      pulmonary infections. There are few data in the literature regarding its treatment apart from
      two small randomized trials (42 and 34 patients, respectively) and a French retrospective
      study (136 patients). So, we decided to conduct a prospective randomized multicenter study to
      evaluate two treatment regimens for Mycobacterium xenopi pulmonary infection in 6-months
      sputum conversion.

      Main objective: To determine the 6-months sputum conversion rate with a clarithromycin or
      moxifloxacin containing regimen in patients with M.xenopi pulmonary infections according to
      ATS / IDSA 2007 criteria.

      Secondary Objectives: To compare the rate of sputum conversion after 3 and 6 months of
      treatment the clinical and radiological outcome and the 12 months mortality.

      primary endpoint : Result of culture of respiratory samples 6 months after starting
      treatment.Culture samples taken 6 months after starting treatment against M. xenopi is either
      positive (presence of M. xenopi colonies with or without smear positive) or negative with
      smear and culture negative (see data collection and measurement methods).

      Study plan: Any patient with at least one positive pulmonary M. xenopi sample may be
      eligible. If the patient underwent ATS / IDSA 2007 criteria of M. xenopi pulmonary infection
      (after clinical , radiological and microbiological evaluation), in the absence of exclusion
      criteria, the patient will be randomized to one of the two treatment arms (rifampicin+
      ethambutol + clarithromycin or rifampicin + ethambutol + moxifloxacin). A clinical,
      radiological, microbiological and pharmacological monitoring will be done for each randomized
      patient. The recommended treatment duration is 12 months after conversion with a maximum
      duration of 18 months.

      Number of patients required: This is a prospective randomized study with 2 parallel groups.
      The primary endpoint is considered for the whole study population. For an α risk of 5%, an
      accuracy of 10%, an expected conversion rate of 70% a total of 80 patients is required . For
      a 15% rate of non evaluable patients (died, lost of follow-up) we need to include 92
      patients.

      Study Duration: Inclusion for 24 months with a minimum follow-up of 6 months (to meet the
      main objective), and if possible a follow-up of 12 months per patient to meet the overall
      objectives of the study.

      Prospects: To establish new treatment recommendations for M.xenopi pulmonary infection, based
      on microbiological and clinical efficacy criteria and tolerance criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum conversion at 6 months under three antibiotics treatment (Rifampin, ethambutol and a third drug clarithromycin or moxifloxacin)</measure>
    <time_frame>6 months</time_frame>
    <description>Results of the smear and culture of three respiratory samples after 6 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum conversion at 3, 6, 9 and 12 months of treatment in the two different arms (clarithromycin containing regimen versus moxifloxacin containing regimen</measure>
    <time_frame>12 months</time_frame>
    <description>At each endpoint (3, 6, 9 and 12 months), respiratory sample will be analyzed (smear and culture) to answer the second objective (to compare microbiological efficacy of clarithromycin-containing regimen versus moxifloxacin-containing regimen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and radiological outcome after 3, 6 and 12 months of treatment according to the treatment arm</measure>
    <time_frame>12 months</time_frame>
    <description>At each end-point (3, 6 and 12 months) :
clinical evaluation with analogic scale (sputum, cough, dyspnea, chest pain, hemoptysis) and weight
radiological evaluation: comparison of the size and number of lesions at each endpoint with basal data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality after 12 months of treatment in the two compared regimen</measure>
    <time_frame>12 months</time_frame>
    <description>Mortality status will be evaluated after 12 months of treatment. In case of deaths under treatment, the date will be collected. Comparative survival analysis will be realized between the two arms of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal toxicity and hematotoxicity after 1- 3- 6- 9- 12- months of treatment</measure>
    <time_frame>12 months</time_frame>
    <description>At each end point (1- 3- 6- 9- 12 months), Rhodes score (gastro-intestinal tolerance)and WHO score for hematological, and gastrointestinal toxicity will be collected in the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Atypical; Mycobacterium, Pulmonary, Tuberculous</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>500 mg twice a day seven days a week</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <other_name>ZECLAR, NAXY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg per day seven days a week</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>IZILOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient and/or legal representative of the patient has provided a written informed
             consent before inclusion in the study

          -  The patient is aged 18 or older

          -  The patient has signs of functional respiratory (cough, sputum, hemoptysis, dyspnea,
             chest pain and / or general signs (asthenia and / or anorexia and / or weight loss)

          -  The patient has a creatinine clearance above 30 ml / min

          -  The patient underwent a thoracic scan not older than one month before the first
             positive bacteriological sample.

          -  The patient underwent a bronchoscopy with sampling conducted in the territory
             corresponding to the radiographic

          -  The most plausible alternative diagnostics have been eliminated using the thoracic
             scan and bronchoscopy

          -  The patient has at least two positive cultures for M. xenopi sputum collected on two
             separate days AND/OR a positive culture for M. xenopi in a bronchoalveolar lavage or
             bronchial aspiration directed AND / OR transbronchial biopsy or lung biopsy with
             surgical histology for a mycobacterial infection (granuloma or Ziehl positive) and a
             culture positive M. xenopi, AND / OR biopsy with histology compatible with
             mycobacteriosis and one or more positive sputum culture for M . xenopi

          -  The patient is willing and able to take the study treatment throughout the duration

          -  If this is a woman of childbearing age, the patient is ready to use for the duration
             of the test contraception method other than estrogen-progestin

          -  The patient did not participate in another study evaluating an investigational drug
             within 30 days prior to enrollment in the study and agrees not to participate in
             another study for the duration of the study

          -  The patient is informed by the doctor and agreed that its data are processed in this
             study

          -  The patient understands / reads French and has no difficulty understanding the
             objectives of the study

          -  The patient has health insurance coverage

        Exclusion Criteria:

          -  Hypersensitivity to any of the molecules (rifampicin, ethambutol, moxifloxacin,
             clarithromycin)

          -  Any patient with a relapse of a lung infection with M. xenopi

          -  The patient is treated with molecules that can interfere with cytochrome P450 and can
             not be replaced by another therapeutic class

          -  The patient is treated by prolonging the QT molecules which can not be replaced by
             another therapeutic class

          -  The patient is treated with alkaloid of ergot, cisapride, biperidil, pimozide,
             mizolastine

          -  The patient has heart failure with left ventricular ejection fraction below 30%

          -  Discovered on the balance sheet or history, we find that the patient infection with
             human immunodeficiency virus HIV 1 and 2 a long QT on ECG and / or arrhythmias or
             clinically significant bradycardia judged by the investigator cytolysis with
             transaminases increase more than 5 times normal renal failure with creatinine
             clearance below 30 ml / min

          -  The patient has cirrhosis Child Pugh C and / or porphyria

          -  There pregnancy or during breastfeeding

          -  The patient has an inability to meet the protocol requirements, including active
             substance abuse, according to the investigator.

          -  The patient has a history of tendinopathy with a fluoroquinolone

          -  The patient has a congenital galactosemia, malabsorption of glucose and galactose, or
             lactase deficiency

          -  The patient has a NORB (abnormalities of the visual field or color vision tested by an
             eye examination prior)

          -  Any other situation that, in the opinion of the investigator, would imply that
             participation in the study is not in the interest of the patient

          -  There is a risk of difficulty of monitoring, such as imminent transfer to a different
             region or country
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire ANDREJAK, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire, Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire ANDREJAK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent JOUNIEAUX, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas VEZIRIS, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP Pitie Salpetriere Hospital, National Center Of Mycobacteria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques CADRANEL, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tenon Hospital APHP Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois-Xavier LESCURE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tenon hospital APHP Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire ANDREJAK, Dr</last_name>
    <phone>+33 3 22 45 59 05</phone>
    <email>clandrejak@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie Liabeuf, Pr</last_name>
    <phone>+33 3 22 45 60 85</phone>
    <email>liabeuf.sophie@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire ANDREJAK, MD</last_name>
      <phone>+33322455907</phone>
      <email>clandrejak@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Vincent JOUNIEAUX, MD</last_name>
      <phone>+33322455905</phone>
      <email>jounieaux.vincent@chu-amiens.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Claire ANDREJAK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent JOUNIEAUX, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc SCHMIT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascaline PRIOU, MD</last_name>
      <phone>+332 41 35 36 95</phone>
      <email>pascaline.priou@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Pascaline PRIOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert DE CREMOUX, MD</last_name>
      <phone>+331 34 23 14 74</phone>
      <email>hubert.decremoux@ch-argenteuil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Juliette CAMUSET, MD</last_name>
      <phone>+331 34 23 14 74</phone>
      <email>juliette.camuset@ch-argenteuil.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurence Courdavault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hubert De Cremoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette Camuset, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Charles DALPHIN, MD PhD</last_name>
      <phone>+33 3.81.66.88.02</phone>
    </contact>
    <investigator>
      <last_name>Jean-Charles DALPHIN, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris CHU Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique VALEYRE, MD PhD</last_name>
      <phone>+33 1 48 95 51 21</phone>
      <email>dominique.valeyre@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique VALEYRE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest La Cavale</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURAUD, MD PhD</last_name>
      <phone>+332 98 34 73 50</phone>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Francis COUTURAUD, 29609</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Béthune</name>
      <address>
        <city>Béthune</city>
        <zip>62408</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic BART, MD</last_name>
      <phone>+333 21 64 43 35</phone>
      <email>fbart@ch-bethune.fr</email>
    </contact>
    <investigator>
      <last_name>Frederic BART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard ZALCMAN, MD-PhD</last_name>
      <phone>+332 31 06 46 77</phone>
      <email>zalcman-g@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Gérard ZALCMAN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06401</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PERRIN, MD</last_name>
      <phone>+334 93 69 71 10</phone>
      <email>c.perrin@ch-cannes.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe PERRIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand Hôpital Gabriel Mont pied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier LESENS, MD PhD</last_name>
      <phone>+33 4 73 75 26 59</phone>
      <email>olesens@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier LESENS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Compiègne</name>
      <address>
        <city>Compiègne</city>
        <zip>60321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie DEHETTE, MD PhD</last_name>
      <phone>+00 3 44 23 62 64</phone>
      <email>s.dehette@ch-compiegne.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie DEHETTE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LOUTSKI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Intercommunal de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno HOUSSET, MD PhD</last_name>
      <phone>+33 1 57 02 20 70</phone>
      <email>bruno.housset@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno HOUSSET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MASSIN, MD</last_name>
      <phone>+333 80 29 32 49</phone>
      <email>francois.massin@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>François MASSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Gonesse</name>
      <address>
        <city>Gonesse</city>
        <zip>95503</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence GERBER, MD</last_name>
      <phone>+331 34 53 20 14</phone>
      <email>florencegerber@ch-gonesse.fr</email>
    </contact>
    <investigator>
      <last_name>Florence GERBER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PISON, MD-PhD</last_name>
      <phone>+33 4 76 76 54 79</phone>
      <email>CPison@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe PISON, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Max MAURIN, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris Hôpital Bicetre</name>
      <address>
        <city>Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Xavier BLANC, MD PhD</last_name>
      <phone>+33 1 45 21 25 33</phone>
      <email>xavier.blanc@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>François Xavier BLANC, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le MANS</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois GOUPIL, MD</last_name>
      <phone>+33 2 43 43 43 52</phone>
      <email>fgoupil@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>François Goupil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal Meulan</name>
      <address>
        <city>Les Mureaux</city>
        <zip>78250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne LEROY-TERQUEN, MD PhD</last_name>
      <phone>+ 33 1 30 22 41 10</phone>
      <email>etiennelt@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Etienne LEROY-TERQUEN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hassen BELKACEMI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille Hôpital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean- Francois BERVAR, MD</last_name>
      <phone>+33 3 20 44 43 18</phone>
      <email>j-bervar@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Jean François BERVAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit GUERY, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges Hôpital de Cluzeau</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris MELLONI, MD-PhD</last_name>
      <phone>+33 5 55 05 68 81</phone>
      <email>boris.melloni@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Boris MELLONI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale NESME, MD</last_name>
      <phone>+33 4 72 07 17 32</phone>
      <email>pascale.nesme-meyer@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale NESME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud BOURDIN, MD</last_name>
      <phone>+33 4 67 33 61 18</phone>
      <email>a-bourdin@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud BOURDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre MALLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David BOUTOILLE, MD</last_name>
      <phone>+33 2 40 47 66 18</phone>
      <email>david.boutoille@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>David Boutoille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Hugo MARQUETTE, MD-PhD</last_name>
      <phone>+33 4 92 03 88 83</phone>
      <email>marquette.ch@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Charles-Hugo MARQUETTE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Bergeron-Lafaurie, MD PhD</last_name>
      <phone>+33 1 42 49 41 65</phone>
      <email>anne.bergeron-lafaurie@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Bergeron-Lafaurie, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christos CHOUAID, MD PhD</last_name>
      <phone>+33 1 49 28 25 16</phone>
      <email>christos.chouaid@sat.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Christos CHOUAID, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre National de Reference Des Mycobactéries</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris Hôpital BICHAT</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno CRESTANI, MD PhD</last_name>
      <phone>+33 1 40 25 68 00</phone>
      <email>bruno.crestani@bch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Crestani, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Thabut, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hervé Mal, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris, hôpital TENON</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques CADRANEL, MD PhD</last_name>
      <phone>+331 56 01 61 47</phone>
      <email>jacques.cadranel@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques CADRANEL, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Xavier LESCURE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carine GREIB, MD</last_name>
      <phone>+335 57 65 64 83</phone>
      <email>carine.greib@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cendrine GODET, MD</last_name>
      <phone>+335 49 44 44 22</phone>
      <email>c.godet@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Cendrine GODET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaëtan Deslee, MD PhD</last_name>
      <phone>+333 26 78 76 09</phone>
      <email>gdeslee@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Gaëtan Deslee, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe STRADY, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes Hôpital Ponchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane JOUNEAU, MD</last_name>
      <phone>+332 99 28 24 78</phone>
      <email>stephane.jouneau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane JOUNEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Tattevin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Roubaix</name>
      <address>
        <city>Roubaix</city>
        <zip>59056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François STEENHOUVER</last_name>
      <phone>+333 20 99 31 31</phone>
      <email>francois.steenhouwer@ch-roubaix.fr</email>
    </contact>
    <investigator>
      <last_name>François Steenhouver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean François MUIR, MD PhD</last_name>
      <phone>+332 32 88 90 83</phone>
      <email>jean-francois.muir@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François MUIR, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc THIBERVILLE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sofiane Benhadji, MD</last_name>
      <phone>+334 77 82 83 14</phone>
    </contact>
    <investigator>
      <last_name>Sofiane Benhadji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Saint Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youcef DOUADI, MD</last_name>
      <phone>+333.23067536</phone>
      <email>ydouadi@bbox.fr</email>
    </contact>
    <investigator>
      <last_name>Youcef Douadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe FRAISSE, MD</last_name>
      <phone>+333 69 55 02 09</phone>
      <email>philippe.fraisse@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe FRAISSE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah ABBES, MD</last_name>
      <phone>+335 67 77 17 75</phone>
      <email>abbes.s@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Sarah ABBES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yazdan Yazdanpanah, MD PhD</last_name>
      <phone>+33 3 20 69 46 17</phone>
      <email>yyazdanpanah@ch-tourcoing.fr</email>
    </contact>
    <investigator>
      <last_name>Yazdan Yazdanpanah, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours Hôpital BRETONNEAU</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain MARCHAND ADAM, MD</last_name>
      <phone>+33 2 47 47 37 87</phone>
      <email>s.marchandadam@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain MARCHAND ADAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PHILIPPE LANOTTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Troyes</name>
      <address>
        <city>Troyes</city>
        <zip>10003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabienne SANLAVILLE, MD PhD</last_name>
      <phone>+ 33 3 25 49 70 42</phone>
      <email>fabienne.sanlaville@ch-troyes.fr</email>
    </contact>
    <investigator>
      <last_name>Fabienne SANLAVILLE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno STACH, MD</last_name>
      <phone>+33 3 27 32 53 90</phone>
      <email>bruno.stach@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno STACH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Vandeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois CHABOT, MD PhD</last_name>
      <phone>+333 83 15 40 21</phone>
      <email>f.chabot@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>François CHABOT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>TIMPE A, RUNYON EH. The relationship of atypical acid-fast bacteria to human disease; a preliminary report. J Lab Clin Med. 1954 Aug;44(2):202-9.</citation>
    <PMID>13184228</PMID>
  </reference>
  <reference>
    <citation>RUNYON EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959 Jan;43(1):273-90.</citation>
    <PMID>13612432</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. Review. Erratum in: Am J Respir Crit Care Med. 2007 Apr 1;175(7):744-5. Dosage error in article text.</citation>
    <PMID>17277290</PMID>
  </reference>
  <reference>
    <citation>Falkinham JO 3rd. Nontuberculous mycobacteria in the environment. Clin Chest Med. 2002 Sep;23(3):529-51. Review.</citation>
    <PMID>12370991</PMID>
  </reference>
  <reference>
    <citation>von Reyn CF, Waddell RD, Eaton T, Arbeit RD, Maslow JN, Barber TW, Brindle RJ, Gilks CF, Lumio J, Lähdevirta J, et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J Clin Microbiol. 1993 Dec;31(12):3227-30.</citation>
    <PMID>8308115</PMID>
  </reference>
  <reference>
    <citation>Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax. 1983 May;38(5):373-7.</citation>
    <PMID>6879487</PMID>
  </reference>
  <reference>
    <citation>Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax. 1984 May;39(5):376-82.</citation>
    <PMID>6740540</PMID>
  </reference>
  <reference>
    <citation>American Thoracic Society. Diagnosis standards and classification of tuberculosis and other mycobacterial diseases. New York: American Lung Association, 1974:25</citation>
  </reference>
  <reference>
    <citation>Wallace RJ, O'Brien R, Glassroth J, Raleigh J, Dutt A. American Thoracic Society. Diagnosis and treatment of disease caused by non tuberculous mycobacteria. Am Rev Respir Dis 142:940-53, 1990</citation>
  </reference>
  <reference>
    <citation>Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 2):S1-25. Review.</citation>
    <PMID>9279284</PMID>
  </reference>
  <reference>
    <citation>Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 2000 Mar;55(3):210-8.</citation>
    <PMID>10679540</PMID>
  </reference>
  <reference>
    <citation>Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, Lozniewski A, Maugein J; French Mycobacteria Study Group. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J. 2006 Dec;28(6):1211-5.</citation>
    <PMID>17138678</PMID>
  </reference>
  <reference>
    <citation>Jenkins PA, Campbell IA; Research Committee of The British Thoracic Society. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir Med. 2003 Apr;97(4):439-44.</citation>
    <PMID>12693807</PMID>
  </reference>
  <reference>
    <citation>Baugnée PE, Pouthier F, Delaunois L. [Pulmonary mycobacteriosis due to Mycobacterium xenopi&quot; in-vitro sensitivity to classical antitubercular agents and clinical development]. Acta Clin Belg. 1996;51(1):19-27. French.</citation>
    <PMID>8669159</PMID>
  </reference>
  <reference>
    <citation>Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, Feldman K, Havelkova M, Katila ML, Köksalan K, Pereira MF, Rodrigues F, Pfyffer GE, Portaels F, Urgell JR, Rüsch-Gerdes S, Tortoli E, Vincent V, Watt B; Spanish Group for Non-Tuberculosis Mycobacteria. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis. 2004 Oct;8(10):1186-93.</citation>
    <PMID>15527150</PMID>
  </reference>
  <reference>
    <citation>Yates MD, Pozniak A, Uttley AH, Clarke R, Grange JM. Isolation of environmental mycobacteria from clinical specimens in south-east England: 1973-1993. Int J Tuberc Lung Dis. 1997 Feb;1(1):75-80.</citation>
    <PMID>9441063</PMID>
  </reference>
  <reference>
    <citation>Andréjak C, Lescure FX, Douadi Y, Laurans G, Smail A, Duhaut P, Jounieaux V, Schmit JL. Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. J Infect. 2007 Jul;55(1):34-40. Epub 2007 Mar 13.</citation>
    <PMID>17360040</PMID>
  </reference>
  <reference>
    <citation>Andréjak C, Lescure FX, Pukenyte E, Douadi Y, Yazdanpanah Y, Laurans G, Schmit JL, Jounieaux V; Xenopi Group. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. 2009 Apr;64(4):291-6. doi: 10.1136/thx.2008.096842. Epub 2008 Dec 3.</citation>
    <PMID>19052044</PMID>
  </reference>
  <reference>
    <citation>Costrini AM, Mahler DA, Gross WM, Hawkins JE, Yesner R, D'Esopo ND. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis. 1981 Jan;123(1):104-9.</citation>
    <PMID>7458072</PMID>
  </reference>
  <reference>
    <citation>Andréjak C, Thomsen VØ, Johansen IS, Riis A, Benfield TL, Duhaut P, Sørensen HT, Lescure FX, Thomsen RW. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010 Mar 1;181(5):514-21. doi: 10.1164/rccm.200905-0778OC. Epub 2009 Dec 10.</citation>
    <PMID>20007929</PMID>
  </reference>
  <reference>
    <citation>Dautzenberg B, Papillon F, Lepitre M, Truffot-Pernod C, Chauvin JP. Mycobacterium xenopi infections treated with clarithromycine-containing regimens. Annual meeting, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy.</citation>
  </reference>
  <reference>
    <citation>Alfandari S. Recommandations du C-CLIN Paris Nord pour le diagnostic et le traitement des infections ostéo-articulaires à Mycobacterium xenopi. Med Mal Infect 28 :231-234, 1998.</citation>
  </reference>
  <reference>
    <citation>Klemens SP, Cynamon MH. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother. 1994 Jul;38(7):1455-9.</citation>
    <PMID>7979271</PMID>
  </reference>
  <reference>
    <citation>Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother. 2001 Nov;45(11):3229-30.</citation>
    <PMID>11600387</PMID>
  </reference>
  <reference>
    <citation>Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008 Jul;63(7):627-34. doi: 10.1136/thx.2007.087999. Epub 2008 Feb 4. Erratum in: Thorax. 2008 Sep;63(9):844.</citation>
    <PMID>18250184</PMID>
  </reference>
  <reference>
    <citation>Varadi RG, Marras TK. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. 2009 Oct;13(10):1210-8. Review.</citation>
    <PMID>19793424</PMID>
  </reference>
  <reference>
    <citation>Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1766-72.</citation>
    <PMID>8665032</PMID>
  </reference>
  <reference>
    <citation>Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995 Apr;107(4):1035-40.</citation>
    <PMID>7705112</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ Jr. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis. 2000 Feb;30(2):288-92.</citation>
    <PMID>10671330</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis. 1996 Nov;23(5):983-9.</citation>
    <PMID>8922790</PMID>
  </reference>
  <reference>
    <citation>Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999 Sep;160(3):866-72.</citation>
    <PMID>10471610</PMID>
  </reference>
  <reference>
    <citation>Dauendorffer JN, Laurain C, Weber M, Dailloux M. In vitro sensitivity of Mycobacterium xenopi to five antibiotics. Pathol Biol (Paris). 2002 Dec;50(10):591-4.</citation>
    <PMID>12504367</PMID>
  </reference>
  <reference>
    <citation>Berlin OG, Young LS, Floyd-Reising SA, Bruckner DA. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria. Eur J Clin Microbiol. 1987 Aug;6(4):486-7.</citation>
    <PMID>2959472</PMID>
  </reference>
  <reference>
    <citation>Fraschini F, Scaglione F, Pintucci G, Maccarinelli G, Dugnani S, Demartini G. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother. 1991 Feb;27 Suppl A:61-5.</citation>
    <PMID>1827103</PMID>
  </reference>
  <reference>
    <citation>Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):215-21.</citation>
    <PMID>8477575</PMID>
  </reference>
  <reference>
    <citation>Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999 Sep;44(3):393-5.</citation>
    <PMID>10511409</PMID>
  </reference>
  <reference>
    <citation>Alcaide F, Calatayud L, Santín M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004 Dec;48(12):4562-5.</citation>
    <PMID>15561826</PMID>
  </reference>
  <reference>
    <citation>Rodriguez Díaz JC, López M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents. 2003 Jun;21(6):585-8.</citation>
    <PMID>12791475</PMID>
  </reference>
  <reference>
    <citation>Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003 Dec 1;168(11):1342-5. Epub 2003 Aug 13.</citation>
    <PMID>12917230</PMID>
  </reference>
  <reference>
    <citation>Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis. 2003 Jun 15;187(12):1977-80. Epub 2003 Jun 4.</citation>
    <PMID>12792877</PMID>
  </reference>
  <reference>
    <citation>Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, Young LS. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother. 2001 Jan;45(1):217-22.</citation>
    <PMID>11120969</PMID>
  </reference>
  <reference>
    <citation>Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2003 Oct;47(10):3117-22.</citation>
    <PMID>14506018</PMID>
  </reference>
  <reference>
    <citation>Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother. 2003 Feb;15(1):66-70.</citation>
    <PMID>12678417</PMID>
  </reference>
  <reference>
    <citation>Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99. Review.</citation>
    <PMID>17883288</PMID>
  </reference>
  <reference>
    <citation>Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007 Feb;51(2):576-82. Epub 2006 Dec 4.</citation>
    <PMID>17145798</PMID>
  </reference>
  <reference>
    <citation>Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998 Feb;113(2):272-7.</citation>
    <PMID>9498938</PMID>
  </reference>
  <reference>
    <citation>Bégaud B, Evreux JC, Jouglard J, Lagier G. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie. 1985 Mar-Apr;40(2):111-8. French.</citation>
    <PMID>4002188</PMID>
  </reference>
  <reference>
    <citation>Rhodes VA, McDaniel RW. The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. Oncol Nurs Forum. 1999 Jun;26(5):889-94.</citation>
    <PMID>10382187</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycobacterium Xenopi Pulmonary Infection</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

